Equity Overview
Price & Market Data
Price: $1.84
Daily Change: +$0.09 / 4.89%
Range: $1.77 - $1.87
Market Cap: $10,177,721
Volume: 16,428
Performance Metrics
1 Week: 2.22%
1 Month: 11.26%
3 Months: -17.49%
6 Months: -40.84%
1 Year: -59.91%
YTD: -44.07%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.